Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by ​strong demand for its eczema drug Dupixent and ‌a high-dose version of its eye drug Eylea.

Follow the biggest business stories of the day with Reuters. Subscribe for $1/week.

 

Reuters Business

Reuters Business

 

Regeneron beats quarterly estimates on eczema drug strength, shares rise 

 

Trump’s DOJ charged hundreds with assaulting officers. Many cases were dropped, but the damage was done   

 

Qualcomm shares slide as higher costs, Apple-related weakness cloud profit forecast 

 

Why Americans are leasing fewer cars 

 

KKR's profit beats estimates on dealmaking strength, asset growth 

 

US stock futures rise as Microsoft offsets Fed concerns 

 

Meta's AI splurge lays bare its compute conundrum 

 

Bombardier tops profit estimates, free cash flow turns positive on strong jet demand 

 

Yum posts solid results, cyclospora outbreak threatens Taco Bell momentum 

 

Altria misses quarterly profit estimates as premium cigarette demand weakens 

 

Sponsors are not involved in the creation of newsletters or other Reuters news content. Advertise in this newsletter or on Reuters' website

LiveIntent Logo
AdChoices Logo
 

Reuters Business is sent every weekday. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here.

Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here.

This email includes limited tracking for Reuters to understand whether you’ve engaged with its contents. For more information on how we process your personal information and your rights, please see our Privacy Statement.

Terms & Conditions

 

© 2026 Thomson Reuters. All rights reserved.
3 Times Square, New York, NY 10036